<SEC-DOCUMENT>0001104659-25-063688.txt : 20250627
<SEC-HEADER>0001104659-25-063688.hdr.sgml : 20250627
<ACCEPTANCE-DATETIME>20250627170704
ACCESSION NUMBER:		0001104659-25-063688
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250627
DATE AS OF CHANGE:		20250627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EYENOVIA, INC.
		CENTRAL INDEX KEY:			0001682639
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				471178401
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282458
		FILM NUMBER:		251087666

	BUSINESS ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		813-766-9539

	MAIL ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2519005d1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5in; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-282458</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Prospectus
Supplement</B></FONT><B><BR>
(To Prospectus Supplements Dated June 2, 2025, April 17, 2025 and December 30, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>To Prospectus dated October 8, 2024)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2519005d1_424b5img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Up to $14,942,887</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement (&ldquo;Prospectus Supplement&rdquo;) amends
and supplements the information in the prospectus dated October 8, 2024 (the &ldquo;Prior Prospectus&rdquo;), filed with the Securities
and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-282458) (the &ldquo;Registration Statement&rdquo;),
as previously supplemented by the prospectus supplements dated December 30, 2024, April 17, 2025 and June 2, 2025 (together with the Prior
Prospectus, the &ldquo;Prospectus&rdquo;). This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified
by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus.
This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus and any future
amendments or supplements thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We previously entered into an amended and restated sales agreement
(the &ldquo;Sales Agreement&rdquo;) with Chardan Capital Markets, LLC (&ldquo;Chardan&rdquo;), dated as of December 30, 2024, relating
to the offer and sale of shares of our common stock, $0.0001 par value per share (the &ldquo;common stock&rdquo;), having an aggregate
offering price of up to $50,000,000 from time to time through Chardan acting as our agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are filing this Prospectus Supplement to amend the Prospectus to
update the amount of shares we are eligible to sell under General Instruction I.B.6 of Form S-3 and pursuant to the Sales Agreement. As
of June 27, 2025, the aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form
S-3 was approximately $52,801,640, which was calculated based on 4,853,092 shares of our outstanding common stock held by non-affiliates
on June 27, 2025 at a price of $10.88 per share, the closing price of our common stock on June 27, 2025. Pursuant to General Instruction
I.B.6 of Form S-3, in no event will we sell, pursuant to the Registration Statement of which this Prospectus Supplement and the Prospectus
form a part, securities in a public primary offering with a value of more than one-third of the aggregate market value of our common stock
held by non-affiliates in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates is less
than $75,000,000. During the 12 calendar months prior to, and including, the date of this Prospectus Supplement, we have sold approximately
$2,657,659 of securities pursuant to General Instruction I.B.6 of Form S-3. As a result of the limitations of General Instruction I.B.6,
and in accordance with the terms of the Sales Agreement, we are registering the offer and sale of shares of our common stock having an
aggregate offering price of up to $14,942,887 from time to time through Chardan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on The Nasdaq Capital Market under the symbol
 &ldquo;EYEN.&rdquo; On June 27, 2025, the last reported sale price of our common stock on The Nasdaq Capital Market was $10.88 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk. See
 &ldquo;Risk Factors&rdquo; beginning on page S-6 of the Prospectus, the &ldquo;Risk Factors&rdquo; section in our most recent Annual Report
on Form 10-K and in our Current Report on Form 8-K filed on June 27, 2025, each of which is incorporated by reference into this Prospectus
Supplement and the Prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated
by reference into this Prospectus Supplement and the Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Prospectus Supplement or the
Prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chardan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
date of this Prospectus Supplement is June 27, 2025. </B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2519005d1_424b5img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2519005d1_424b5img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G 3,# 2(  A$! Q$!_\0
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M4+D9(S^[,8[9YJM<J6G!@<7(,I5)+<9\^0<M)-$?3VI;"7<OEP74!BD&XYD
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M8F8!1'V0'\^N#WX[]:9<:@#;2R GR]R[6QQ@ \YQCTZUS?VGR0R2!3<EC'*
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M!M1AL[JZYNK&Y&8)CZ^QK1\#> 9/#=[>:SJU\=2UZ_QY]R1@*/[J^W^ KN:
M/,O^$B^*RR>0?!VEL_\ SV%Y^[_G4$/@'Q)XMU:WU#Q[J%LUI;MOATFS'[K/
M^T>_ZUZK10!P6J>$]2NOBWH?B.!(?[.LK62&7Y\,"0X&!^(KO!12T 9NN6DM
M]H&H64&WSI[:2*/)P,LI KD/!W@1K;X8Q^%?$<$,N[S!*D;9'+9!!]17H%%
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M!YK6CTQT$D6[S#(X>[D@R!*P^[%$O/RC'S#TK5M]))8B15,C/YLY0##,/NQ
MXY5?0^U8N"1K3PIEV&F%('C5 )([5;;A%!$CG+?<Y! /.*Z>ULE4LY3[[@\C
M)(48';^=6(+)(E4$;MI+<\Y8]3S5L# Q65CT*5%1%  Z4M%%!N%%%% !1110
M 4E+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 A&:B>VB<Y:-&/^T,T44 0R64<CAF)9U.5+<[?H.G>C[%""V!@
MOPQ[L/0GTYHHJKBY43);1QD%4 (&![5(JA0 !@"BBI&.HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
